Mediphage, a preclinical-stage biotechnology company, is developing a next-generation gene therapy platform based on its proprietary ministring DNA (msDNA) technology. A Toronto-based company, founded in 2016, Mediphage’s platform supports a broad set of applications, from gene addition to gene editing, and in various indications, including CNS, retinal, and liver disorders. msDNA is designed to overcome critical challenges facing viral-based gene therapies while leveraging advancements in the delivery of nucleic acids.

Mediphage Bioceuticals Logo



Event details

Date: June 13 - 16, 2022

Event contact

Patricia Cosgrove
Area Director
USA: Life Sciences


26 in total